SBIR-STTR Award

JAK2 Gene Correction Using an Engineered Homing Endonuclease
Award last edited on: 7/17/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$100,000
Award Phase
1
Solicitation Topic Code
393
Principal Investigator
Derek Jantz

Company Information

Precision Biosciences Inc

302 East Pettigrew Street Suite A-100
Durham, NC 27701
Location: Single
Congr. District: 01
County: Durham

Phase I

Contract Number: 1R43CA134075-01
Start Date: 4/1/2008    Completed: 9/30/2009
Phase I year
2008
Phase I Amount
$100,000
Gene targeting is a general method to mutate or replace genes at specific chromosomal sites in intact cells. The method relies on the production of a site-specific double-strand DNA break at the locus of interest, which is subsequently repaired by recombination with a homologous transgene. Precision BioSciences has developed a method for the production of "custom" endonucleases capable of targeting such DNA breaks to unique chromosomal sites with genome-level specificity. One of these enzymes, EndoJAK2, was designed to recognize a site in the human JAK2 gene, which is associated with a wide range of myeloproliferative disorders. This proposal outlines a set of experiments to investigate the ability of the EndoJAK2 endonuclease to direct the modification of the chromosomal JAK2 gene in a human cell line. If successful, these experiments will not only promote the development of a novel cancer gene therapy but will validate a general method for in situ genome modification in human cells.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----